Ya disponible nuestro libro, Protocolo clínico #cáncerdepróstata.Lo podéis encontrar en: https://t.co/8p2Kv8yyjM Práctica clínica y evidencia.Pedimos feedback. @HUCA_Asturias @FINBAsturias @puntorojolibros

How long should ADT really be with definitive RT 🚨 NEW JAMA ONCOLOGY META-ANALYSIS 10,266 pts • 13 RCTs • MARCAP IPD 🎯 Key Finding : 📉 Benefit rises rapidly up to ~12 months 🛑 After 12 months → benefit plateaus ⚠️ But OCM (non–prostate cancer deaths) steadily

Gracias por la invitación a SidebySide. Hablamos de #cáncerdepróstata y casos complejos. Con @agomeziturriaga Nicolás Feltes @HUCA_Asturias

La detección precoz del cáncer de testículo es vital para lograr la curación, y para ello es muy importante la autoexploración. Por eso, te damos las claves para realizarla de manera correcta y detectar cualquier cambio que debas tratar con tu urólogo. #MovemberAEU25

Incorporamos los microultrasonidos, en diagnóstico de #cáncerdeprostata en @HUCA_Asturias . @Crispiess88 R. Sacristán González. Mayor precisión complementando a la biopsia transperineal por fusión @jesusmfergomez Exactimaging

Excelente jornada para hablar sobre #cáncerdepróstata con A.Iglesias, @Uro_Dominguez , J. Cardenal @HUCA_Asturias Gracias a johnson&johnson 🔵Estratificar riesgo en localizado 🔵RTR+24m de TPA en R.alto riesgo 🔵Doblete para todos, triplete para algunos 🔵Rt próstata en CPHsm

◽La consejera de Salud inaugura el encuentro informativo 𝗘𝗙𝗘 𝗙𝗼́𝗿𝘂𝗺 '𝗧𝗶𝗲𝗺𝗽𝗼 𝘆 𝗰𝗮́𝗻𝗰𝗲𝗿 𝗱𝗲 𝗽𝗿𝗼́𝘀𝘁𝗮𝘁𝗮 𝗲𝗻 𝗔𝘀𝘁𝘂𝗿𝗶𝗮𝘀: 𝗽𝗼𝗿 𝘂𝗻 𝗱𝗶𝗮𝗴𝗻𝗼́𝘀𝘁𝗶𝗰𝗼 𝗽𝗿𝗲𝗰𝗼𝘇' que se celebra en el Edificio Histórico de la Universidad de Oviedo, al que

📢 The November issue of Actas Urológicas Españolas is here! Access all articles from Vol. 49, No. 9 at this link👉 🔗 https://t.co/cPt3YnbV0W #ActasUrológicasEspañolas #urología #RevistaCientífica #AEU #UrologíaEspañola #InvestigaciónMédica

PRESTO Presented at #ESMO25 A phase III open-label study of combined androgen blockade in patients with high-risk biochemically relapsed #ProstateCancer https://t.co/LCeGVBo0RZ PRESTO evaluated whether adding apalutamide (APA) with or without abiraterone💊 acetate plus

#cáncerdepróstata #cáncertestículo #saludmental #concienciación #Unidadegestiónurologíahuca @jesusmfergomez @HUCA_Asturias @astursalud

🚨23 years of PSA screening in @NEJM 🚨 👉ERSPC RCT of >162k patients 📅Median 23 year f/u PSA screening lead to... 📉 #prostatecancer mortality by 13% ✅1 death prevented for every 456 men invited for screening or 12 diagnosed w/ PCa 📉Risk of advanced PCa by 34% ⭐️Benefit

@DrYukselUrun @theNCI @DrMHofman @AzadOncology @Silke_Gillessen @neerajaiims @ZilliThomas @piet_ost @yekeduz_emre @declangmurphy @dmukherji @GGiannarini Thanks 🎈Excellent members on the working group who understand nuances of BCR 🎈Pragmatic recommendations in the context of existing data @davidjeinstein #BCR #ProstateCancer #PSMA+BCR 🔗Link to 📖 article @JCO_ASCO @ASCO https://t.co/ePbf8j7KQU

El medicamento trampa, generosamente prescrito por servicios hospitalarios y recomendado por "guías". https://t.co/ZkMtdC6m7y y 👇

2420MO – STOPCAP Meta-analysis #ESMO25 📊 Pooled IPD from PEACE-1 & STAMPEDE: prostate RT in synchronous mHSPC. ⚖️ No overall OS benefit (HR 0.93, p=0.11) ✅ Low-volume benefit: HR 0.79 → +7.7% 5-yr OS ✅ ≤4 bone mets: HR 0.84 (+4.9%) ➡️ Benefit confined to low-volume,

Excellent talk on somatic and germline testing of advanced #prostatecancer by @Cpaller #ESMO25 👉All these pts should get tested. Guidelines by different countries👇Limitations and conclusions👇@OncoAlert @urotoday @PCF_Science

Just in from #ESMO25 Berlin👉Phase III PSMAAddition trial shows that adding ¹⁷⁷Lu-PSMA-617 to ADT + ARPI significantly improved rPFS (HR 0.72; p = 0.002) in PSMA-positive mHSPC, with consistent benefit across subgroups. OS immature. #ProstateCancer @OncoAlert @UroToday

🎯 CAPItello-281: Dual blockade delivers in PTEN-deficient mHSPC! 💊 Capivasertib + Abiraterone + ADT vs placebo + Abiraterone + ADT 📍 n = 1012 | Phase III | PTEN-deficient mHSPC 📈 Primary rPFS: 33.2 mo vs 25.7 mo ⏱ (HR 0.81 [0.66-0.98], p = 0.034) Consistent benefit across

Trail del prerrománico Oviedo. Hecho(12k)🏃🏻‍♂️

Fantastic talk by @DrPaulNguyen #ESMO25 👉result of ph3 Enzarad trial👉Addition of ENZA to ADT + radiation did not improve MFS in all high risk localized, the primary endpoint. However, node+ on CT/MRI pts derived benefit, like Stampede trial @OncoAlert @urotoday @PCF_Science

Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science

“Can surgery still matter in metastatic prostate cancer?” 🩺 💥 RAMPP trial says maybe yes - even in low-volume mHSPC. 🧪 Design: De novo low-volume mHSPC (≤5 bone mets ± nodes) 👥 Fit for RP + systemic therapy (ADT ± ARPI) 🆚 Radical prostatectomy (RP) + BST vs BST alone 🎯